Molnupiravir 200 mg Capsules

Molnupiravir Manufacturer

Molnupiravir (development codes MK-4482 and EIDD-2801) is an orally active experimental antiviral medication that was designed to treat viruses. It is a class of drug of the synthetic nucleoside derivative N4-hydroxycytidine that works against viruses by causing copying errors during viral RNA replication.

The drug was developed at Emory University by the university's drug innovation company, Drug Innovation Ventures at Emory (DRIVE). It was then acquired by Miami-based company Ridgeback Biotherapeutics, who later partnered with Merck & Co. to develop the drug further.

Uses of Molnupiravir

• Drastically reduce the number of days you’re infected.
• Stop the infection from spreading and causing C-19 problems and consequences.
• Suppress virus transmission and slow the spread of the virus in the community.

Mild C-19 patients benefit from molnupiravir (molnuvid 200 mg)because it speeds up their recovery

RxCare's sole intention is to ensure that its consumers get expert-reviewed, accurate, and trustworthy information. However, the information contained herein should NOT be used as a substitute for the advice of a qualified physician. The information provided here is for informational purposes only. This may not cover all possible side effects, drug interactions, or warnings, or alerts. Would you please consult your doctor and discuss all your queries related to any disease or medicine? We intend to support, not replace, the doctor-patient relationship.

NOTE: Actual product image and manufacturing brand may vary!